A team led by Professor Eijiro Miyako at Tohoku University’s Institute of Multidisciplinary Research for Advanced Materials has now developed a multifunctional nanomedicine designed to confront several of these biological obstacles at once. The platform, named B-LM-DMX-αCD25, combines gallium-based liquid-metal nanoparticles, a photothermal agent, a stimulator of interferon genes (STING) agonist, and an antibody directed against CD25, a surface marker highly expressed by Tregs. Rather than relying on a single mechanism, the system is engineered to coordinate tumor ablation, selective immune suppression reversal, and innate immune activation. In studies conducted in drug-resistant TNBC mouse models, the treatment produced complete regression of tumors, sharply reduced lung metastases, and extended survival, suggesting that the approach could transform a localized treatment into a systemic anticancer response.

At the center of the platform are liquid-metal nanoparticles based on gallium, a metal that remains liquid near room temperature and can be engineered into nanoscale structures with useful optical and chemical properties. The particles function as photothermal transducers: after absorbing near-infrared light, they convert electromagnetic energy into heat. The reported photothermal conversion efficiency exceeds 54 percent, allowing the nanoplatform to generate substantial temperatures under external laser irradiation. This property is especially valuable in cancer therapy because the particles can be activated at the tumor site rather than continuously exposing the entire body to a toxic drug. The researchers further coated the nanoparticles with components derived from whole blood, creating a biomimetic shell intended to make the construct appear more like a natural biological entity to the immune system.

This blood-cell camouflage is designed to reduce rapid clearance by the mononuclear phagocyte system, a network of immune cells in organs such as the liver and spleen that commonly captures intravenously administered nanoparticles. According to the researchers, the coating enabled the particles to accumulate in tumors at approximately five times the efficiency of conventional nanoparticles. Improved tumor localization is a crucial technical advantage because it can increase the concentration of therapeutic material where it is needed while limiting exposure in healthy tissues. The strategy also illustrates a broader direction in nanomedicine: instead of constructing completely artificial particles that the body immediately identifies as foreign, scientists are using biological membranes and blood-derived components to borrow the body’s own mechanisms of circulation and immune evasion.

Once the camouflaged nanoparticles reach a tumor, the treatment is activated with near-infrared laser light. In the mouse experiments, irradiation raised the tumor temperature to approximately 58 degrees Celsius within five minutes. This level of heating causes direct thermal destruction of malignant cells, but the researchers are also exploiting a second consequence: immunogenic cell death. Unlike ordinary cell death, which may leave the immune system largely unaware, immunogenic cell death releases tumor-associated antigens and danger-associated molecular patterns. These molecular signals can stimulate antigen-presenting cells and help them process tumor material, potentially turning the treated tumor into an in situ source of personalized cancer vaccines. In effect, the photothermal component does not merely burn cancer cells; it helps expose their molecular identity to the immune system.

The platform’s antibody component is intended to remove one of the most important immune restraints inside TNBC tumors. Tregs normally protect the body from excessive or misdirected immune activity, but tumors can recruit and exploit these cells to suppress cytotoxic T lymphocytes and maintain an immunologically “cold” environment. B-LM-DMX-αCD25 carries anti-CD25 antibodies on its surface, allowing it to target CD25-rich Tregs within the tumor. The selective depletion of these cells is designed to release what the researchers describe as an immunological brake. This approach differs from indiscriminate immune stimulation because it focuses immune-modulating activity at the disease site and aims to reduce suppressive cells before activating tumor-directed immunity.

The third mechanism is supplied by DMX, a STING agonist incorporated into the nanoplatform for laser-triggered release. The STING pathway is part of the innate immune system and responds to abnormal cytosolic DNA, a signal associated with infection and cellular damage. When activated in the tumor microenvironment, STING signaling can promote dendritic-cell maturation and stimulate production of type I interferons, including interferon-β. These cytokines help bridge innate and adaptive immunity by improving antigen presentation and supporting the expansion and function of tumor-specific cytotoxic T cells. In the B-LM-DMX-αCD25 design, photothermal heating therefore performs two coordinated tasks: it causes immunogenic tumor destruction and releases the STING agonist at the site of treatment.

The resulting sequence is intended to create a positive feedback loop. Anti-CD25 targeting reduces local immune suppression, while photothermal therapy supplies tumor antigens and danger signals. STING activation then enhances dendritic-cell activity and interferon signaling, helping the immune system convert those tumor-derived materials into a stronger adaptive response. The activated T cells can travel beyond the irradiated lesion, potentially recognizing and attacking cancer cells at distant sites. This systemic effect is particularly important in TNBC, which can spread aggressively to the lungs and other organs. The researchers’ results support that possibility: treatment suppressed pulmonary metastases by more than 90 percent in orthotopic mouse models, indicating that the therapy’s impact extended beyond the area directly exposed to the laser.

Molecular and cellular analyses of treated tumors showed extensive immune remodeling. The investigators reported more than a 13-fold increase in CD3-positive T cells and an approximately 11-fold increase in dendritic cells within the tumor tissue. CD3 is a component of the T-cell receptor complex and serves as a broad marker of T-cell presence, while dendritic cells are essential for capturing antigens and presenting them to T lymphocytes. Together, these findings suggest that the therapy changed the tumor from an immune-excluded environment into one with substantially greater immune-cell infiltration and antigen-presenting capacity. In the drug-resistant TNBC models, the treatment achieved complete tumor regression in all animals and extended median survival beyond 70 days. These results are striking, but they remain preclinical: responses in mice do not establish safety, dosing, or effectiveness in human patients.

The researchers are now considering how the platform could be adapted for other solid tumors characterized by strong immune suppression, including pancreatic and ovarian cancers. They are also developing formulations compatible with NIR-II light, which penetrates tissue more effectively than the near-infrared wavelengths commonly used in first-generation photothermal systems. Greater penetration could make it possible to treat tumors located deeper inside the body, although precise control of heating and protection of surrounding tissue will remain essential. At the same time, the team is preparing GLP-compliant repeat-dose toxicology studies, an important step toward evaluating biodistribution, immune reactions, organ toxicity, clearance, and the effects of repeated administration. The findings, published in Advanced Science, present B-LM-DMX-αCD25 as a highly integrated experimental strategy: a blood-camouflaged liquid-metal nanoplatform that combines targeted Treg depletion, laser-driven immunogenic tumor destruction, and STING-amplified systemic immunity in an effort to overcome the biological defenses of metastatic triple-negative breast cancer.

Subject of Research: A blood-cell-camouflaged liquid-metal nanoplatform for treating metastatic triple-negative breast cancer through Treg depletion, photothermal therapy, and STING pathway activation.

Article Title: Blood Cell-Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING-Amplified Photothermal Immunity for Metastatic Triple-Negative Breast Cancer Therapy

News Publication Date: 11 August 2026

Web References: https://doi.org/10.1002/advs.77069

References: Advanced Science, DOI: 10.1002/advs.77069

Image Credits: Eijiro Miyako

Keywords: Triple-negative breast cancer, cancer immunotherapy, nanomedicine, liquid-metal nanoparticles, photothermal therapy, STING agonist, regulatory T cells, dendritic cells, tumor immunogenicity, metastasis, biomimetic nanoparticles, Tohoku University

The structural delicacy of gold nanoparticles, however, poses a significant challenge in their repeated medical application. Their distinctive bipyramidal morphology—resembling two pyramids conjoined at their bases—is critical to their efficiency in generating localized heat. Yet, ironically, the heat generated during therapy undermines their own structural integrity. Thermal exposure initiates a morphological transformation where the sharp, precise edges of the bipyramids gradually smooth into more rounded forms. This loss of geometric precision diminishes the nanoparticles’ directional heat focus, thereby weakening their therapeutic potency over time.

A breakthrough in stabilizing these nanoparticles emerged from a collaborative international investigation involving research teams from the Universities of Córdoba, Strasbourg, and the Sorbonne. Their study identified a novel molecular strategy to protect the nanoparticle’s surface, specifically targeting the plasmonic layer—the critical interface where laser light is absorbed and converted into heat. By coating this outermost layer with a specially selected polymer, the team effectively engineered a protective shell that not only shields the nanoparticle during heating but also preserves its defining bipyramidal shape.

Among various molecular candidates assessed, a long-chain polymer demonstrated superior performance in stabilizing the gold nanoparticles. Unlike traditional ligands, such as sodium citrate—which, while biocompatible, proved insufficient in maintaining particle morphology under photothermal conditions—the polymer exhibits a unique affinity for strategically positioning itself on targeted nanoparticle regions. This selective adhesion results in a robust protective barrier, minimizing structural alterations during heat exposure, and extending the functional lifespan of the nanoparticles within therapeutic contexts.

The choice of polymer over citrate was unexpected, considering the latter’s widespread use and natural occurrence in fruits like lemons and oranges. Although citrate is non-toxic and generally favorable for biological applications, the study revealed its inadequacy in preserving nanoparticle morphology during intense photothermal processes. This counterintuitive finding underscores the complex interplay between molecular coating properties and nanoparticle stability, emphasizing that biocompatibility alone is not sufficient when designing nanoparticles for repeated or prolonged use in heat-based cancer therapies.

One of the most compelling aspects of this research is the application of liquid cell transmission electron microscopy (LCTEM), a cutting-edge technique that allows real-time visualization of nanoparticle behavior under irradiation. Through LCTEM, researchers observed the dynamic morphological changes as nanoparticles were subjected to laser-induced heat, capturing the gradual transition from defined bipyramids to distorted shapes. This direct imaging provided unparalleled insights into the oxidation and etching processes impacting the nanoparticles, enabling precise evaluation of the protective efficacy offered by different molecular coatings.

The study delicately balanced interdisciplinary expertise, drawing from material science, nanotechnology, and medical research to engineer a solution that bridges laboratory innovation with clinical potential. Through the synergy of microscopy advancements and chemical engineering, it pushes the frontiers of functional nanomaterial design, opening pathways to more resilient photothermal agents that could revolutionize non-invasive cancer treatments.

Fundamentally, this work addresses one of the pivotal obstacles limiting the broader adoption and durability of nanoparticle-based photothermal therapies: the intrinsic instability induced by therapeutic heat itself. By reinforcing the particle surface against oxidative etching and morphological degradation, the stabilized nanoparticles demonstrate prolonged photothermal performance, suggesting a direct translation to improved therapeutic outcomes where repeated or extended treatments are necessary.

The research, authored by Irene López Sicilia and colleagues including Valentina Girelli Consolaro and Sophie Marbach, is a testament to the impact of international and multidisciplinary cooperation in advancing biomedical nanotechnology. The innovative approach and data detailed in their publication in Advanced Functional Materials highlight the evolving understanding of nanoparticle surface chemistry and its critical ramifications for therapy longevity.

Looking ahead, these findings may influence the development of next-generation nanoparticle constructs tailored for enhanced durability under operational stresses, broadening the utility of photothermal therapy beyond oncology into other medical fields where targeted heat application is beneficial. Moreover, the demonstration that non-biocompatible polymers can outperform traditional bio-friendly ligands in certain contexts challenges the conventional paradigm guiding nanoparticle design.

The intersection of real-time microscopy techniques with molecular engineering heralds an era where nanoparticle therapies can be fine-tuned at the nanoscale level, ultimately enhancing specificity, efficacy, and safety profiles. This advancement underscores a significant step towards personalized nanomedicine, where particle design is optimized not only for initial impact but also for sustained activity throughout therapeutic regimens.

In summary, the stabilization of gold bipyramidal nanoparticles via polymer coating represents a critical innovation for photothermal cancer therapy. By protecting the plasmonic surface and mitigating heat-induced degradation, these enhanced nanoparticles promise to extend the window of efficacy for laser-based cancer treatments, potentially minimizing treatment frequency and side effects while maximizing tumor destruction.

As this research community continues to refine the molecular interfaces governing nanoparticle stability and function, the promise of photothermal therapy as a safer, more targeted alternative to conventional chemotherapy draws closer to widespread clinical reality. The collective insights gained exemplify how minute alterations at the molecular scale can cascade into profound improvements in patient care and therapeutic precision.

Subject of Research: Stabilization of gold bipyramidal nanoparticles for enhanced photothermal therapy efficacy in cancer treatment.

Article Title: Elucidating the Role of Surface Ligands on the Oxidative Etching of Au Bipyramids During Photothermia Using Liquid Cell Transmission Electron Microscopy.

News Publication Date: 9 March 2026.

Web References:
http://dx.doi.org/10.1002/adfm.202600034

References:
I. López-Sicilia, V. Girelli Consolaro, S. Marbach, et al. “Elucidating the Role of Surface Ligands on the Oxidative Etching of Au Bipyramids During Photothermia Using Liquid Cell Transmission Electron Microscopy.” Advanced Functional Materials (2026): e00034.

Image Credits: University of Córdoba.

Keywords: Nanoparticles, Gold Nanoparticles, Photothermal Therapy, Cancer Treatment, Nanomaterials, Surface Ligands, Polymer Stabilization, Liquid Cell Transmission Electron Microscopy, Oxidative Etching, Nanoparticle Morphology, Biomedical Nanotechnology.

This pioneering work, spearheaded by Professor Eijiro Miyako at Tohoku University in collaboration with researchers from the French National Centre for Scientific Research (CNRS) and the University of Strasbourg, represents a conceptual leap forward in the realm of nanomedicine and cancer therapy. Rather than delivering the P-gp inhibitors and chemotherapeutic drugs simultaneously, the researchers engineered nanoparticles to first disable the drug expulsion mechanism before releasing the anticancer agents. This temporal control over drug release exploits the concept that repairing or neutralizing a cell’s drug resistance pumps must precede the effective deployment of chemotherapy. The analogy Miyako draws is apt: “You need to patch up a hole in a leaky bucket before adding more water, instead of trying to do both at the same time.”

The design of these nanoparticles is both elegant and intricate. Constructed from porous amino acid-based materials, these nanoparticles encapsulate two key therapeutic agents: the P-gp inhibitor quinidine and the chemotherapeutic drug doxorubicin (Dox). Their structure allows for controlled, sequential release—initially liberating quinidine to inhibit P-gp activity, followed by a delayed release of doxorubicin once the drug efflux pumps are effectively neutralized. This sequential approach is complemented by an integrated photothermal therapy function, where near-infrared (NIR) laser irradiation heats the tumor locally, enhancing cytotoxicity and facilitating tumor destruction while sparing normal tissues.

The nanoplatform’s capability for active tumor targeting further enhances its therapeutic index. This targeting is achieved by functionalizing the nanoparticle surface, ensuring preferential accumulation within tumor microenvironments. Such specificity minimizes systemic exposure and adverse side effects, a critical factor in clinical oncology. The exquisite control over spatiotemporal drug release, combined with tumor-specific targeting and adjunct photothermal therapy, establishes a multifaceted assault against MDR cancers.

In vitro assays validate the superiority of this approach. Cancer cells exposed to the sequential delivery system exhibited markedly higher accumulation of doxorubicin compared to cells treated with chemotherapy or photothermal therapy alone. The inhibition of P-gp pumps prior to drug release significantly elevated intracellular drug concentrations, overcoming MDR at the cellular level. These findings were bolstered by in vivo studies in a mouse model bearing drug-resistant tumors. Mice receiving the combined nanoparticle therapy demonstrated complete tumor regression and achieved 100% survival, with no signs of toxicity to normal organs—outcomes that far outstrip conventional treatments.

The photothermal component, activated by near-infrared laser light, serves dual purposes. It not only directly induces tumor cell death via hyperthermia but also enhances nanoparticle permeability and drug penetration within tumors. This synergistic effect magnifies the therapeutic impact, fostering an environment unfavorable to tumor survival and recurrence. Importantly, the use of amino acid-derived building blocks in nanoparticle construction underscores the potential biocompatibility and clinical translatability of this system, addressing a significant hurdle in nanoparticle-based drug delivery.

Multidrug resistance remains a pervasive and complex challenge across many cancer types, often leading to treatment failure and disease progression. The strategy presented in this research transcends traditional methodologies by employing a rational, mechanistically informed sequence of therapeutic actions. Targeting the resistance mechanism at its root, prior to administering cytotoxic agents, re-sensitizes tumors to chemotherapy and allows for the reinstitution of effective cancer cell eradication.

Professor Miyako envisions this work as a foundational step toward developing clinically viable nanoparticle systems that can revolutionize treatment paradigms for resistant cancers. The ability to program drug release kinetics and integrate multiple therapeutic modalities within a single nanoscale platform offers unprecedented control over treatment efficacy and safety. Such advancements are poised to dramatically improve patient outcomes and expand the arsenal against cancers that have eluded conventional therapies.

The convergence of nanotechnology, pharmacology, and photothermal therapy exemplified in this study reflects the cutting edge of personalized and precision medicine. By tailoring therapy not only to the molecular profile of cancer cells but also to the temporal dynamics of drug resistance, this approach represents a beacon of hope for the oncology community. As this platform advances toward clinical translation, it holds the promise of transforming once intractable cancers into manageable or even curable conditions.

This remarkable study underscores the critical importance of multidisciplinary collaboration in addressing complex biomedical challenges. The synergy between Japanese and French research teams combined expertise in materials science, molecular biology, and clinical oncology to design a solution that could redefine therapeutic strategies against MDR cancer. Such cooperation paves the way for future innovations that harness the versatility of nanomaterials and the precision of modern biomedical engineering.

Beyond its immediate therapeutic implications, this research sets a precedent for the future design of nanoparticle-based drug delivery systems that can achieve sequenced and multi-modal interventions. The principles elucidated here can be extended to other diseases characterized by cellular resistance mechanisms, opening new frontiers in nanomedicine. This platform’s modularity and adaptability render it a versatile tool in the ongoing quest to overcome cellular drug resistance across a broad spectrum of medical conditions.

In summary, the development of multifunctional amino acid-based nanoparticles capable of sequential drug delivery, combined with photothermal therapy and active tumor targeting, offers a revolutionary strategy to surmount multidrug resistance in cancer. Achieving complete tumor regression and 100% survival in animal models heralds a new era of promise for effective and safe cancer treatment. As this technology advances towards clinical application, it promises to deliver transformative benefits to patients worldwide grappling with resistant malignancies.

Subject of Research: Multifunctional amino acid-based nanoparticles for overcoming multidrug resistant cancer through sequential drug delivery and photothermal therapy.

Article Title: Multifunctional amino acid-based nanoparticles for sequential drug delivery to overcome multidrug resistant cancer

News Publication Date: 6-May-2026

Web References:
http://dx.doi.org/10.1016/j.jconrel.2026.114954

Image Credits: ©Eijiro Miyako et al.

Keywords: Cancer, Multidrug resistance, Chemotherapy, Nanoparticles, Drug delivery systems, Amino acid nanoparticles, Photothermal therapy, P-glycoprotein inhibition, Sequential drug release, Tumor targeting, Doxorubicin, Quinidine

Gold nanoparticles have long been recognized for their unique optical and thermal properties, making them invaluable in medical applications such as photothermal therapy (PTT). This technique involves directing a laser at AuNPs concentrated within tumors. The nanoparticles absorb the light and convert it into localized heat, elevating the temperature enough to selectively ablate cancerous tissue without damaging nearby healthy cells. However, conventional chemical synthesis of AuNPs often employs toxic reagents, requires extensive energy input, and results in nanoparticles with variable stability and biocompatibility, limiting clinical potential.

The Osaka team’s discovery pivots on leveraging microalgal biomass as a biological “nanofactory.” The microalgae produce a complex matrix of biomolecules — including proteins, pigments, and antioxidants — which act as natural reducing and stabilizing agents. When exposed to chloroauric acid (HAuCl₄), these biomolecules facilitate the reduction of Au³⁺ ions to elemental gold, simultaneously capping and functionalizing the nanoparticles to prevent aggregation and enhance stability. This bio-mediated process, conducted under mild conditions, circumvents the need for hazardous chemicals or high temperatures characteristic of traditional methods.

Extensive characterization revealed that the bio-synthesized AuNPs (“Bio@AuNPs”) boast exceptional photothermal conversion efficiency and thermal stability. These nanoparticles exhibited a uniform spherical morphology with controlled size distribution, key factors for predictable in vivo behavior. Furthermore, in vitro assays demonstrated selective cytotoxicity toward cancer cells upon laser irradiation, while maintaining minimal toxicity to normal cells. This selective biocompatibility is attributed to the natural organic coating derived from algal biomolecules, which appears to mitigate unwanted interactions with healthy tissues and reduce oxidative stress.

Beyond therapeutic efficacy, the implications for sustainable manufacturing are profound. The microalgae-based synthesis drastically reduces environmental burdens: the process requires less energy, produces negligible chemical waste, and uses renewable biological materials. In the context of global efforts aligned with the United Nations Sustainable Development Goals (SDGs), this innovation represents an important step toward greener nanotechnology in healthcare.

The stability of these “Bio@AuNPs” under photothermal conditions is particularly noteworthy. Traditional AuNPs often suffer from degradation or morphological changes upon repeated laser exposure, leading to diminished treatment effectiveness and potential safety concerns. The algae-derived nanoparticles maintain their photothermal properties over extended periods, ensuring reliable performance during therapy sessions.

Professor Madoka Suzuki, lead investigator of the study, highlights that this work not only paves the way for safer cancer therapies but also offers a novel platform for exploring cellular thermoregulation. Understanding how living cells detect and respond to localized heat generated by such nanoparticles could unlock new insights in cell biology and aid in designing even more precise therapeutics.

Crucially, this work addresses persistent challenges in nanomedicine — toxicity, stability, and scalability — by integrating biological systems with nanomaterial science. The use of living organisms to fabricate high-value nanoparticles introduces a level of functional complexity and biocompatibility that synthetic chemistry struggles to achieve alone.

The study included rigorous experimental validation, comparing the biological synthesis technique against traditional chemical methods. It confirmed that the Bio@AuNPs’ functionalization by microalgal biomolecules leads to enhanced stability in physiological conditions and impressive photothermal responsiveness. Such attributes make these nanoparticles ideal candidates for clinical translation in photothermal cancer therapy and potentially other modalities requiring localized heat generation.

In addition to therapeutic applications, functionalized AuNPs synthesized via green methods may find utility in diagnostic imaging, drug delivery, and biosensing. Their natural coatings facilitate further surface modification for targeted delivery or multimodal treatment strategies, broadening their impact beyond photothermal therapy.

The transformational potential of microalgae-mediated nanoparticle synthesis extends well beyond the laboratory. By establishing a sustainable, scalable route that aligns with environmental imperatives, this approach could redefine the future landscape of nanoparticle fabrication in medicine, reducing costs and environmental impact while enhancing patient safety.

This pioneering research demonstrates how interdisciplinary collaboration across bioengineering, materials science, and environmental chemistry can produce innovations that resonate with global health and ecological priorities. As the demand for precision nanomedicine grows, sustainable synthesis strategies like this will be critical to delivering safe, effective therapies worldwide.

The article detailing these findings, titled “Microalgae-Mediated Synthesis of Functionalized Gold Nanoparticles with High Photothermal Stability,” appeared in the peer-reviewed journal ACS Sustainable Chemistry & Engineering. This work is supported by prominent Japanese research institutions, including the Japan Society for the Promotion of Science and the Takeda Science Foundation, underscoring the importance of sustained investment in green nanotechnology.

Subject of Research: Not applicable
Article Title: Microalgae-Mediated Synthesis of Functionalized Gold Nanoparticles with High Photothermal Stability
News Publication Date: 7-Nov-2025
Web References: http://dx.doi.org/10.1021/acssuschemeng.5c07786
References: DOI: 10.1021/acssuschemeng.5c07786
Image Credits: Reham Samir Hamida and Madoka Suzuki
Keywords: Medical technology, Nanomedicine, Green chemistry, Cancer research, Gold nanoparticles, Reactive oxygen species, Surface modification, Microalgae